[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pmmrmss\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pmmrmss":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100652836","phase-2-16-hour-fasting-plus-serplulimab-and-capeox-as-neoadjuvant-therapy-in-pmmrmss-advanced-mid-to-low-rectal-cancer-100652836",false,"NCT07779694","16-Hour Fasting Plus Serplulimab and CAPEOX as Neoadjuvant Therapy in pMMR\u002FMSS Advanced Mid-to-Low Rectal Cancer","Neoadjuvant 16-Hour Fasting Combined With Serplulimab and CAPEOX for pMMR\u002FMSS Locally Advanced Mid-to-Low Rectal Cancer: A Prospective, Single-Arm, Phase II Trial.","Inclusion Criteria:\n\n1. Willing and able to provide written informed consent.\n2. Male or female subjects ≧ 18 years ≦ 75 of age.\n3. Histological or cytological documentation of adenocarcinoma of the rectum.\n4. No previous any systemic anticancer therapy for rectal cancer disease.\n5. The primary rectal tumor is assessed as likely to be R0 resectable by a multidisciplinary colorectal cancer collaborative team, comprising at least 2 gastrointestinal surgeons and 1 radiologist.\n6. The lower margin of the tumor is less than 10cm from the anus verge.\n7. cT2N1-2M0, cT3N0-2M0, cT4N0-1M0 MSS with MRF(-) assessed by MRI.\n8. Primary tumor can be detected by CT or MRI.\n9. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n10. Eligible tumor tissues were identified for MSI\u002FMMR assays.\n11. Hepatitis B Surface Antigen (HBsAg) (-).\n12. If HBsAg (+) , HBV-DNA must be less than 2500 copies\u002FmL or 500 IU\u002FmL to be enrolled.\n13. Patients with HCV antibody (-) or HCV-RNA negative can be enrolled. Aspartate aminotransferase (AST) must be ≤ 3 x ULN for the lab. If HCV-RNA is positive, patients with both alanine aminotransferase (ALT) and aspartate aminotransferase (AST) performed ≤3×ULN could be enrolled. Patients infected with both hepatitis B virus and hepatitis C virus should be excluded (positive for HBsAg or HBcAb and positive for HCV antibodies).\n\nExclusion Criteria:\n\n1. Patients with recurrent rectal cancer or a history of pelvic radiotherapy.\n2. Patients with a history of inflammatory bowel disease.\n3. Patients with acquired immunodeficiency syndrome (AIDS-related illnesses) or known human immunodeficiency virus (HIV) disease (HIV1 antibody, HIV2 antibody, HTLV1 antibody positive) should be excluded.\n4. Patients who are preparing for or have previously received an organ or bone marrow transplant.\n5. History of myocardial infarction, poorly controlled arrhythmias (including QTc interval ≥470 ms in women) in the 6 months prior to enrollment (QTc interval calculated by Fridericia formula).\n6. According to New York College of Cardiology (NYHA) standards for Grade III-IV cardiac insufficiency or cardiac color ultrasound: left ventricular ejection fraction (LVEF) \\\u003C50%.Poor hypertension control (systolic blood pressure ≥150 mmHg and\u002For diastolic blood pressure ≥100 mmHg), a past hypertensive crisis or hypertensive encephalopathy.\n7. Poor hypertension control (systolic blood pressure ≥150 mmHg and\u002For diastolic blood pressure ≥100 mmHg), a past hypertensive crisis or hypertensive encephalopathy.\n8. Patients had undergone major surgery within 28 days prior to enrollment. Patients with tumor biopsy or lymph node dissection biopsy were admitted. Patients undergoing enterostomy due to intestinal obstruction were admitted.\n9. The patients had previously been treated with other antibodies\u002Fdrugs that target immune checkpoints, such as PD-1, PD-L1, and cytotoxic T lymphocyte-associated Antigen 4 (CTLA-4).\n10. Patients are participating in other clinical studies, or plan to start this study treatment less than 14 days from the end of the previous clinical study.\n11. Uncontrolled tumor-related pain.\n12. A known history of severe allergy to any monoclonal antibody.\n13. Known to be allergic or intolerance to any oxaliplatin and capecitabine ingredients.\n14. Pregnant or lactating women.\n15. The investigators determined that the patient had other factors that might have led to the early termination of the study.","ALL","18 Years","75 Years",{"count":20,"type":21},51,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Although standard neoadjuvant chemoradiotherapy (nCRT) for locally advanced rectal cancer (LARC) effectively reduces local recurrence, radiotherapy-related toxicities and surgical complications severely impair patients' quality of life, making a radiotherapy-free strategy urgently needed. However, chemotherapy alone yields a pathological complete response (pCR) rate of only 6.6%-15%, which is far from satisfactory.\n\nThe pMMR\u002FMSS subtype, accounting for 90% of rectal cancers, is \"immune-cold\" and shows almost no response to PD-1 monotherapy; nonetheless, chemotherapy can reshape the tumor immune microenvironment, and multiple studies have demonstrated that combining chemotherapy with PD-1 inhibitors (without radiotherapy) can elevate pCR rates to 26.8%-42.9%, yet further improvement remains desirable. A recent mechanistic study published in Cell Metabolism (2026) revealed that a single 16-hour fasting episode before treatment promotes isoleucine accumulation in the tumor microenvironment, which enhances CD8+T-cell cytotoxic function and reduces exhaustion through acetyl-CoA metabolism and epigenetic reprogramming, thereby significantly sensitizing PD-1 inhibitors-and this intervention is non-invasive, low-cost, and easily adoptable by patients.\n\nBased on the above evidence, we hypothesize that the neoadjuvant triple-combination regimen of \"16-hour fasting + chemotherapy + PD-1 inhibitor\" (radiotherapy-free) in pMMR\u002FMSS locally advanced mid-to-low rectal cancer may further increase pCR rates and tumor regression, offering a novel, highly effective, and low-toxicity therapeutic option for LARC patients.",[27,28,29],"pMMR\u002FMSS","Locally Advanced Rectal Carcinoma","Fasting, Intermittent",[31,32,33,34,35],"Rectal cancer","Serplulimab","CAPEOX","neoadjuvant therapy","16-hour fasting","NOT_YET_RECRUITING","2026-08-18",{"date":39,"type":40},"2026-08-21","ACTUAL",{"date":42,"type":21},"2026-09-01",{"date":44,"type":21},"2029-12-31",{"name":46,"class":47},"Zhejiang University","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100633502","phase-2-neoadjuvant-moderately-hypofractionated-radiotherapy-combined-with-chemotherapy-and-immunotherapy-for-high-risk-pmmrmss-locally-advanced-rectal-cancer-a-prospective-multi-center-randomized-control-phase-ii-trial-100633502","NCT07527520","Neoadjuvant Moderately Hypofractionated Radiotherapy Combined With Chemotherapy and Immunotherapy for High-risk pMMR\u002FMSS Locally Advanced Rectal Cancer: A Prospective, Multi-center Randomized Control Phase II Trial","Inclusion Criteria:\n\n* Age ≥ 18 years and ≤ 75 years.\n* Histologically confirmed colorectal adenocarcinoma with the lower margin of the lesion ≤ 10 cm from the anal verge as assessed by MRI, and immunohistochemistry confirming pMMR, or genetic testing demonstrating MSI-L or MSS.\n* Presence of at least one of the following high-risk factors as assessed by pelvic MRI: cT4a\u002Fb; N2; extramural vascular invasion (EMVI+); mesorectal fascia involvement (MRF+); enlarged lateral lymph node (longest diameter \\> 7 mm).\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1\n* No prior surgery, radiotherapy, chemotherapy, or targeted therapy.\n* Able to tolerate radiotherapy, chemotherapy, and immunotherapy: ECOG performance status score 0-2. Laboratory results: white blood cell count ≥ 4.0 × 10⁹\u002FL, platelet count ≥ 100 × 10⁹\u002FL, hemoglobin ≥ 80 g\u002FL, ALT \\\u003C 2 × ULN, total bilirubin \\\u003C 35 μmol\u002FL, serum creatinine \\\u003C 1.5 × ULN or creatinine clearance ≥ 50 mL\u002Fmin, thyroid-stimulating hormone within normal range (patients with stable thyroid function after hormone replacement therapy may be enrolled).\n* Willing to participate and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Presence of distant metastasis.\n* Patients with stage I or II rectal cancer who do not require preoperative neoadjuvant therapy.\n* Severe diseases involving the heart, lung, brain, kidney, gastrointestinal tract, or other systemic conditions.\n* Untreated chronic hepatitis B or HBV carriers with HBV DNA \\> 500 IU\u002FmL, or patients positive for HCV RNA. Patients with inactive hepatitis B surface antigen (HBsAg) carriers, those with hepatitis B who have been treated and are stable (HBV DNA \\\u003C 500 IU\u002FmL), and those who have been cured of hepatitis C may be enrolled.\n* Active autoimmune disease or history of autoimmune disease with potential for relapse.\n* Receipt of corticosteroids (at a dose equivalent to prednisone \\> 10 mg\u002Fday) or other immunosuppressive therapy within 2 weeks prior to study drug administration.\n* History of thyroid dysfunction.\n* Severe chronic or active infection requiring systemic antifungal or antiviral therapy, including tuberculosis infection.\n* History of allergic constitution or allergy to multiple drugs.\n* History of prior pelvic radiotherapy.\n* History of inflammatory bowel disease.\n* Unwillingness to participate or inability to provide written informed consent.",{"count":55,"type":21},165,[24],"This study aims to observe and evaluate the efficacy and safety of moderately hypofractionated radiotherapy combined with chemotherapy and immunotherapy, compared with conventional neoadjuvant chemoradiotherapy, in patients with high-risk locally advanced colorectal cancer.",[59,60,32,27],"Rectal Cancer","Moderately Hypofractionated Radiotherapy","2026-04-07",{"date":63,"type":40},"2026-04-14",{"date":65,"type":21},"2026-06",{"date":67,"type":21},"2031-06",{"name":69,"class":47},"Fudan University",1]